EIF5B/mitogen-activated protein kinase 1 axis drives tumor progression and confers dual resistance to chemotherapy and immunotherapy in colonic adenocarcinoma

doi:10.3748/wjg.121829

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 32, Issue 43

This Article

(1)

(2)

(0)

(27)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastroenterol. Nov 21, 2026; 32(43): 121829
Published online Nov 21, 2026. doi: 10.3748/wjg.121829

Table 4 Association between eukaryotic translation initiation factor 5B and immunophenoscore scores using The Cancer Immunome Atlas database

Characteristics	r value	P value
IPS-CTLA-4-negative-PD-1-negative¹	-0.128	0.019
IPS-CTLA-4-negative-PD-1-positive²	-0.137	0.012
IPS-CTLA-4-positive-PD-1-negative³	-0.172	0.002
IPS-CTLA-4-positive-PD-1-positive⁴	-0.189	< 0.001

¹Predicted efficacy under no anti-cytotoxic T lymphocyte-associated antigen-4/anti-programmed cell death protein 1 blockade.

²Predicted efficacy under anti-programmed cell death protein 1 monotherapy.

³Predicted efficacy under anti-cytotoxic T lymphocyte-associated antigen-4 monotherapy.

⁴Predicted efficacy under combined anti-cytotoxic T lymphocyte-associated antigen-4/anti-programmed cell death protein 1 blockade.

CTLA-4: Cytotoxic T lymphocyte-associated antigen-4; IPS: Immunophenoscore; PD-1: Programmed cell death protein 1.

Full Size Table

Citation: Li WX, Shi QZ, Mu YH, Li CL, Khan S, Zhao WC, Han N. EIF5B/mitogen-activated protein kinase 1 axis drives tumor progression and confers dual resistance to chemotherapy and immunotherapy in colonic adenocarcinoma. World J Gastroenterol 2026; 32(43): 121829
URL: https://www.wjgnet.com/1007-9327/full/v32/i43/121829.htm
DOI: https://dx.doi.org/10.3748/wjg.121829

Li WX, Shi QZ, Mu YH, Li CL, Khan S, Zhao WC, Han N. EIF5B/mitogen-activated protein kinase 1 axis drives tumor progression and confers dual resistance to chemotherapy and immunotherapy in colonic adenocarcinoma. World J Gastroenterol 2026; 32(43): 121829 [DOI: 10.3748/wjg.121829]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.